Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
1 other identifier
observational
540
1 country
9
Brief Summary
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2009
Typical duration for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2009
CompletedFirst Submitted
Initial submission to the registry
August 31, 2010
CompletedFirst Posted
Study publicly available on registry
September 10, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2011
CompletedJanuary 12, 2012
January 1, 2012
2.1 years
August 31, 2010
January 11, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography
patients with left ventricular hypertrophy will be screened for Fabry mutations, and results will be communicated within four months
At baseline T0
Study Arms (1)
left ventricular hypertrophy
Patients with left ventricular hypertrophy will be used.
Interventions
Eligibility Criteria
patients with left ventricular hypertrophy
You may qualify if:
- All patients over 18 years undergoing a routine echocardiography in the participating hospitals
- Both genders will be considered.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
AZ Imelda
Bonheiden, Belgium
AZ Sint-Blasius
Dendermonde, Belgium
AZ Sint-Lucas
Ghent, Belgium
Maria Middelares
Ghent, Belgium
University Hospital Ghent
Ghent, Belgium
Jan Yperman Ziekenhuis
Ieper, Belgium
AZ Oostkust
Knokke-Heist, Belgium
ZOL
Limbourg, Belgium
AZ Zusters van Barmhartigheid
Ronse, Belgium
Related Publications (1)
Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, Hemelsoet D, Pascale H, De Backer J, De Paepe A, Poppe B, Vanholder R. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol. 2013 Sep 10;167(6):2555-60. doi: 10.1016/j.ijcard.2012.06.069. Epub 2012 Jul 16.
PMID: 22805550DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Raymond Vanholder, MD, PhD
University Hospital Ghent, Belgium
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 31, 2010
First Posted
September 10, 2010
Study Start
July 1, 2009
Primary Completion
August 1, 2011
Study Completion
August 1, 2011
Last Updated
January 12, 2012
Record last verified: 2012-01